Markets

Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders

Oct 5, 2026 · 04:10 PM ET· updated 1h ago

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly

Why It Matters

Korro Bio started testing a new medicine on real patients. This is an early step that shows the company is moving forward with its plan.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

KRRO10.00

+0.36 (+3.73%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.